CLIN Clinigen Group Plc

TIDMCLIN

Clinigen Group plc

23 October 2017

RNS Reach

23 October 2017

Clinigen acquires Japan's largest supplier of unlicensed medicines

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has today acquired International Medical Management Corporation ('IMMC'), Japan's largest supplier of unlicensed medicines, for an undisclosed sum.

The acquisition will add to Clinigen's existing footprint in the country following the launch of its Japanese business in October 2016. The acquisition of IMMC is part of Clinigen's strategy to become the 'go to' global leader in ethical access to unlicensed medicines and will allow the Group to better address unmet patient needs.

IMMC, established in 2006, operates throughout Japan in sectors including niche vaccine, oncology and IVF. It currently has relationships with more than 850 hospitals and clinics, which will now be able to benefit from the broader access to medicines available as part of Clinigen.

Japan is the world's second largest pharmaceutical market. The unlicensed medicines market in Japan is underdeveloped, highly regulated and well controlled leading to a high unmet medical need. For instance, from the 154 new drugs launched globally between 2008 and 2012, two thirds still remained unavailable in Japan by 2013, illustrating the difficulties patients in Japan have in accessing approved medicines.

The threat of counterfeit medicines entering the supply chain in Japan, also remains an issue. Japan is the second-largest target of illegal online medicine sellers in the world behind the US.

IMMC was acquired for an upfront cash payment followed by certain potential milestone-based instalments over 12 months.

In the year ended 30 September 2017 the unaudited IMMC gross profit was Yen352m (GBP2.4m).

Shaun Chilton, Group Chief Executive Officer, Clinigen, said:

"This acquisition represents another strategic development, extending our geographical footprint and another step to becoming the global leader in ethical access to unlicensed medicines. The enlarged Japanese operation adds further capability in this high growth market which is crucial to our customers and a key part of Clinigen's global offering."

Yoshiyuki Kudo, President, IMMC, said:

"Clinigen's global expertise and our local knowledge will allow us to better address the unmet patient need in Japan, further benefiting our customers and increasing our offering in access to unlicensed medicines."

- Ends -

Contact details

 
 Clinigen Group plc                  Tel: +44 (0) 1283 
                                      495010 
 Shaun Chilton, Group Chief 
  Executive Officer 
  Martin Abell, Group Chief 
  Financial Officer 
 
 Numis Securities Limited            Tel: +44 (0) 20 7260 
                                      1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 
 RBC Capital Markets - Joint      Tel: +44 (0) 20 7653 
  Broker                           4000 
 Marcus Jackson / Elliot Thomas 
  / Jack Wood 
 
 Instinctif Partners              Tel: +44 (0) 20 7457 
                                   2020 
 Melanie Toyne-Sewell / Alex      Email: clinigen@instinctif.com 
  Shaw 
 

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinical Trial Services

Clinigen is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials.

Unlicensed Medicines

Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides 'on-demand' access globally to medicines which remain unlicensed at the point of care.

Commercial Medicines

The Group acquires global rights to niche hospital-only and critical care products, revitalising these assets around the world and returning them back to sustained growth. The Group also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

For more information on Clinigen, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEASEEALAXFFF

(END) Dow Jones Newswires

October 23, 2017 02:00 ET (06:00 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Clinigen (LSE:CLIN)
Historical Stock Chart
From Jul 2023 to Jul 2024